Inhaled liposomal ciprofloxacin protects against a lethal infection in a murine model of pneumonic plague

Frontiers in Microbiology

Volumn 8, Issue FEB, 2017, Pages

  Hamblin, Karleigh A ^a   Armstrong, Stuart J ^a   Barnes, Kay B ^a   Davies, Carwyn ^a   Laws, Thomas ^a   Blanchard, James D ^b   Harding, Sarah V ^b   Atkins, Helen S ^a,c  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b ARADIGM CORPORATION   (United States)

^c UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Biological warfare agents; Ciprofloxacin; Inhalation exposure; Liposomal drug delivery; Plague; Yersinia pestis

Indexed keywords

CIPROFLOXACIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; BIOLOGICAL WARFARE; BLOOD CULTURE; BREATHING RATE; CONTROLLED STUDY; DIET; DRUG DELIVERY SYSTEM; EXPOSURE; FEMALE; LIQUID CHROMATOGRAPHY; LOCOMOTION; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; SCORING SYSTEM; SEPTICEMIA; SINGLE DRUG DOSE; YERSINIA PESTIS;

EID: 85014565354     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2017.00091     Document Type: Article

References (34)

1. Alving, C. R. (1988). Mononuclear phagocyte system macrophages as targets for delivery of liposome-encapsulated antimicrobial agents. Adv. Drug Deliv. Rev. 2, 107-128. doi: 10.1016/0169-409X(88)90007-5.
2. Bertherat, E. G. (2015). Plague in Madagascar: overview of the 2014-2015 epidemic season. Wkly. Epidemiol. Rec. 90, 250-252.
3. Bruinenberg, P., Blanchard, J., Cipolla, D., Dayton, F., Mudumba, S., and Gonda, I. (2010). "Inhaled liposomal ciprofloxacin: once a day management of respiratory infections," in Respiratory Drug Delivery 2010, eds R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, S. J. Farr, and P. M. Young (River Grove, IL: Davis Healthcare International), 73-82.
4. Bruinenberg, P., Otulana, B., Blanchard, J., Cipolla, D., Wilson, J., and Serisier, D. (2009). Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients. J. Cystic Fibros. 8(Suppl. 2), S49-S49. doi: 10.1016/S1569-1993(09)60196-X.
5. Chono, S., Tanino, T., Seki, T., and Morimoto, K. (2008). Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev. Ind. Pharm. 34, 1090-1096. doi: 10.1080/03639040801958421.
6. Cipolla, D., Blanchard, J., and Gonda, I. (2016). Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics 8:6. doi: 10.3390/pharmaceutics8010006.
7. Cipolla, D., Dayton, F., Fulzele, S. V., Gabatan, E., Mudumba, S., Wu, H., et al. (2010). "Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance," in Respiratory Drug Delivery 2010, eds R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, S. J. Farr, and P. M. Young (River Grove, IL: Davis Healthcare International), 409-414.
8. Conley, J., Yang, H. M., Wilson, T., Blasetti, K., Di Ninno, V., Schnell, G., et al. (1997). Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 41, 1288-1292.
9. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1-10. doi: 10.1086/516284.
10. Crook, L. D., and Tempest, B. (1992). Plague. A clinical review of 27 cases. Arch. Intern. Med. 152, 1253-1256.
11. Dalhoff, A. (2005). Immunomodulatory activities of fluoroquinolones. Infection 33, 55-70. doi: 10.1007/s15010-005-8209-8.
12. Druett, H. A. (1969). A mobile form of the Henderson apparatus. Epidemiol. Infect. 67, 437-448.
13. Guyton, A. C. (1947). Measurement of the respiratory volumes of laboratory animals. Am. J. Physiol. 150, 70-77.
14. Hamblin, K. A., Armstrong, S. J., Barnes, K. B., Davies, C., Wong, J. P., Blanchard, J. D., et al. (2014a). Liposome-encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis Schu S4 strain. Antimicrob. Agents Chemother. 58, 3053-3059. doi: 10.1128/AAC.02555-13.
15. Hamblin, K. A., Wong, J. P., Blanchard, J. D., and Atkins, H. S. (2014b). The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy. Front. Cell. Infect. Microbiol. 4:79. doi: 10.3389/fcimb.2014.00079.
16. Harper, G. J., and Morton, J. D. (1953). The respiratory retention of bacterial aerosols: experiments with radioactive spores. Epidemiol. Infect. 51, 372-385.
17. Harris, S. H. (1993). Factories of Death: Japanese Biological Warfare, 1932-1945, and the American Cover-Up. New York, NY: Routledge.
18. Hart, M. K., Saviolakis, G. A., Welkos, S. L., and House, R. V. (2012). Advanced development of the rF1V and rBV A/B vaccines: progress and challenges. Adv. Prev. Med. 2012:731604. doi: 10.1155/2012/731604.
19. Heine, H. S., Chuvala, L., Riggins, R., Hurteau, G., Cirz, R., Cass, R., et al. (2013). Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice. Antimicrob. Agents Chemother. 57, 2010-2015. doi: 10.1128/AAC.02504-12.
20. Heine, H. S., Louie, A., Adamovicz, J. J., Amemiya, K., Fast, R. L., Miller, L., et al. (2014). Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. Antimicrob. Agents Chemother. 58, 3276-3284. doi: 10.1128/AAC.02420-14.
21. Inglesby, T. V., Dennis, D. T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., et al. (2000). Plague as a biological weapon: medical and public health management. J. Am. Med. Assoc. 283, 2281-2290. doi: 10.1001/jama.283.17.2281.
22. Lettieri, J. T., Rogge, M. C., Kaiser, L., Echols, R. M., and Heller, A. H. (1992). Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36, 993-996. doi: 10.1128/AAC.36.5.993.
23. Norville, I. H., Hatch, G. J., Bewley, K. R., Atkinson, D. J., Hamblin, K. A., Blanchard, J. D., et al. (2014). Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever. Antimicrob. Agents Chemother. 58, 5510-5518. doi: 10.1128/AAC.03443-14.
24. Organisation, W. H. (2016). Plague around the world. Wkly. Epidemiol. Rec. 91, 89-93.
25. Perry, R. D., and Fetherston, J. D. (1997). Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10, 35-66.
26. Raabe, O. G., Al-Bayati, M. A., Teague, S. V., and Rasolt, A. (1988). Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann. Occup. Hyg. 32, 53-63. doi: 10.1093/annhyg/32.inhaled_particles_VI.53.
27. Russell, P., Eley, S. M., Green, M., Stagg, A. J., Taylor, R. R., Nelson, M., et al. (1998). Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J. Antimicrob. Chemother. 41, 301-305. doi: 10.1093/jac/41.4.461.
28. Serisier, D. (2012). Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin. Drugs Today 48, 339-351. doi: 10.1358/dot.2012.48.5.1789474.
29. Serisier, D. J., Bilton, D., De Soyza, A., Thompson, P. J., Kolbe, J., Greville, H. W., et al. (2013). Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 68, 812-817. doi: 10.1136/thoraxjnl-2013-203207.
30. Thomas, R. J., Webber, D., Collinge, A., Stagg, A. J., Bailey, S. C., Nunez, A., et al. (2009). Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small-and large-particle aerosols. Infect. Immun. 77, 1315-1323. doi: 10.1128/IAI.01473-08.
31. Wheelis, M. (2002). Biological warfare at the 1346 siege of caffa. Emerg. Infect. Dis. 8, 971-975. doi: 10.3201/eid0809.010536.
32. Wong, J. P., Schnell, G., Simpson, M., and Saravolac, E. (2000). Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylococcus aureus by murine macrophages. Artif. Cells Blood Substit. Biotechnol. 28, 415-428. doi: 10.3109/10731190009118586.
33. Wong, J. P., Yang, H. M., Blasetti, K. L., Schnell, G., Conley, J., and Schofield, L. N. (2003). Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 92, 265-273. doi: 10.1016/S0168-3659(03)00358-4.
34. Zhou, Q., Leung, S. S. Y., Tang, P., Parumasivam, T., Loh, Z. H., and Chan, H.-K. (2015). Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv. Drug Deliv. Rev. 85, 83-99. doi: 10.1016/j.addr.2014.10.022.